Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

iX Biopharma Ltd. (42C) Share Price & Analysis

26 Followers

42C Stock Chart & Stats

S$0.48-S$0.01(-1.04%)
At close: 5:00 PM GMT+8
S$0.4S$0.5S$0.6Aug 17Aug 31Sep 14Sep 28Oct 12Oct 26Nov 10
Day’s Range
SGD 0.47 - SGD 0.49
52-Week Range
SGD 0.11 - SGD 0.63
Previous Close
SGD 0.48
Volume
N/A
Average Volume (3M)
9.20M
Market Cap
SGD 526.08M
Enterprise Value
SGD 575.20M
Total Cash (Recent Filing)
SGD 14.73M
Total Debt (Recent Filing)
SGD 5.80M
Price to Earnings (P/E)
―
Beta
0.15
Next Earnings
Feb 05, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

WaferiX Platform

The proprietary WaferiX platform gives iX Biopharma a differentiated delivery approach within specialty pharmaceuticals. Its potential convenience and faster onset can support product development, licensing and partner adoption, creating several routes to commercialise the technology over time.

Revenue And Gross Margin

The 2026 recovery in revenue and substantial gross-margin improvement indicate some operating stabilisation after weaker periods. If maintained, better gross economics could improve the contribution from future product sales and partnerships, although profitability has not yet been achieved.

Improved Capital Structure

The much lower leverage ratio and stronger equity base represent a meaningful improvement from the severe 2025 balance-sheet stress. A healthier capital structure can provide greater financial flexibility to support product development and commercialisation, even though losses remain.

Bears Say

Persistent Losses

Persistent net losses and deeply negative operating margins show that the business has not yet converted its platform and products into sustainable profitability. Continued losses can constrain reinvestment, weaken equity over time, and make the path to durable earnings dependent on successful execution.

Negative Cash Generation

Ongoing negative operating and free cash flow means the company is not currently funding its activities from internal cash generation. This cash burn increases dependence on external funding sources and could restrict the pace of development, manufacturing scale-up, or commercial expansion.

Uneven Revenue Trajectory

Although revenue rebounded in 2026, the steep fall from the 2022 peak and only modest growth in 2025 indicate an uneven commercial trajectory. Such volatility makes forward scaling less predictable and raises execution demands for launches, partnerships, and recurring product sales.

iX Biopharma Ltd. News

42C FAQ

What was iX Biopharma Ltd.’s price range in the past 12 months?
iX Biopharma Ltd. lowest share price was S$0.11 and its highest was S$0.63 in the past 12 months.
What is iX Biopharma Ltd.’s market cap?
iX Biopharma Ltd.’s market cap is S$526.08M.
When is iX Biopharma Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were iX Biopharma Ltd.’s earnings last quarter?
iX Biopharma Ltd. released its earnings results on Nov 11, 2026. The company reported -S$0.003 earnings per share for the quarter.
Is iX Biopharma Ltd. overvalued?
According to Wall Street analysts iX Biopharma Ltd.’s price is currently Undervalued.
Does iX Biopharma Ltd. pay dividends?
iX Biopharma Ltd. does not currently pay dividends.
What is iX Biopharma Ltd.’s EPS estimate?
iX Biopharma Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iX Biopharma Ltd. have?
iX Biopharma Ltd. has 1,095,998,300 shares outstanding.
What happened to iX Biopharma Ltd.’s price movement after its last earnings report?
iX Biopharma Ltd. reported an EPS of -S$0.003 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of iX Biopharma Ltd.?
Currently, no hedge funds are holding shares in SG:42C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology